


8-4-05

Ifu



DOCKET NO.: CELG-0422

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jerome B. Zeldis, et al.

Confirmation No.: 8455

Application No.: 10/820,397

Group Art Unit: 1614

Filing Date: April 8, 2004

Examiner: Not Yet Assigned

**For: METHODS FOR TREATMENT OF COGNITIVE AND MENOPAUSAL
DISORDERS WITH D-THREO METHYLPHENIDATE**

EXPRESS MAIL LABEL NO: EV 325730542 US

DATE OF DEPOSIT: August 3, 2005

EV325730542US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **145-147** listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.

DOCKET NO.: CELG-0422


- 3 -

PATENT

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:


August 3, 2005



Walter C. Frank
Registration No. 52,911

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No.
CELG-0422

Application No.
10/820,397

Applicant
Jerome B. Zeldis, et al.

Filing Date
April 8, 2004

Group
1614

Confirmation No.
8455

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
/D.S./	145	4,137,300	01/30/79	Sheth et al.	424	460

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/D.S./	146	96/41617 A1	12/27/96	WO		

Examiner
Initial

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/D.S./	147	Patrick K S et al: "The Absorption Of Sustained-Release Methylphenidate Formulations Compared To An Immediate-Release Formulation" Biopharmaceutics And Drug Disposition, Wiley, Chichester, US, Vol. 10, No. 2, 1989, Pages 165-171

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008